Obama's support of anti-inversion legislation only aims to put a patch on a larger problem—the need for corporate tax reform, CEOs tell CNBC.» Read More
Baxter International Inc. fell$. 09 or. 1 percent, to $76.67. Bristol-Myers Squibb Co. rose$. 17 or. 3 percent, to $48.88. Hospira rose$. 04 or. 1 percent, to $50.79.
Jeffrey Cummings of the Cleveland Clinic said none of the deaths seemed due to the drug and pneumonia occurred at a rate to be expected in older people. Results were revealed Wednesday at the Alzheimer's Association International Conference in Copenhagen.
*Three ex-GSK staff seek labour arbitration in Shanghai. BEIJING/ SHANGHAI, July 16- Three former Chinese employees of GlaxoSmithKline PLC, which is embroiled in a long-running corruption probe in China, are seeking compensation for illegal dismissal from their jobs, a lawyer representing them told Reuters.
Baxter International Inc. rose$. 03 or percent, to $76.62. Bristol-Myers Squibb Co. rose$. 28 or. 6 percent, to $48.90. Hospira rose$. 43 or. 8 percent, to $51.25.
Baxter International Inc. rose$. 20 or. 3 percent, to $76.79. Bristol-Myers Squibb Co. fell$. 04 or. 1 percent, to $48.58. Hospira fell$. 03 or percent, to $50.80.
July 14- Several multi-billion dollar deals and bids have made 2014 a busy year for healthcare acquisitions, despite Pfizer pulling its $118 billion offer for AstraZeneca.
Baxter International Inc. fell$. 54 or. 7 percent, to $76.21. Bristol-Myers Squibb Co. fell$. 07 or. 1 percent, to $48.44. Hospira fell$. 34 or. 7 percent, to $50.72.
Baxter International Inc. fell$. 54 or. 7 percent, to $76.21. Bristol-Myers Squibb Co. fell$. 11 or. 2 percent, to $48.40. Hospira fell$. 22 or. 4 percent, to $50.84.
WASHINGTON, June 27- The U.S. Food and Drug Administration said on Friday it has approved MannKind Corp's inhaled insulin, Afrezza, capping an arduous journey for the company and its octogenarian founder, Alfred Mann. It acts more rapidly than injectable insulins such as Eli Lilly and Co's Humalog and Novo Nordisk's NovoLog.
WASHINGTON, June 27- The U.S. Food and Drug Administration said on Friday it has approved MannKind Corp's inhaled insulin Afrezza, capping an arduous journey for the company and its octogenarian founder, Alfred Mann. It acts more rapidly than traditional injected insulin sold by Eli Lilly and Co and Denmark's Novo Nordisk.
A three-judge panel of the 6th U.S. Circuit Court of Appeals in Cincinnati rejected claims in 67 of the cases. Among the defendants in the various cases were Eli Lilly& Co, which won regulatory approval for Darvon in 1957 and Darvocet in 1972, and generic drug makers such as Mylan Inc and Teva Pharmaceutical Industries Ltd..
*Sanofi hit may be limited as EU market smaller than U.S. LONDON, June 27- European regulators have for the first time recommended approval of a copycat insulin for diabetics, posing a threat to French drugmaker Sanofi whose top-selling Lantus is now set to face a cheaper rival in 2015..
*Novo Nordisk deputy CEO sees group growing 10 pct annually. COPENHAGEN, June 25- Danish drugmaker Novo Nordisk, the world's biggest insulin maker, expects to more than double its annual revenue within a decade, its deputy chief executive Kaare Schultz told Reuters.
The US population is getting grayer, and while getting old stinks, there are plenty of ways to profit from an aging demographic using ETFs.
Medtronic's $43 billion Covidien deal may signal future medical-device company mergers.
Many of the world's biggest drugmakers will gather starting Friday in San Francisco for the American Diabetes Association's annual meeting. Here's what investors need to know.
SHANGHAI, June 13- China's crackdown on corruption in the pharmaceutical sector has frightened foreign executives so much that some fear they could be jailed and have asked their lawyers if they should leave the country for six months.
Some of Wednesday's midday movers:
June 11- Eli Lilly and Co's recently approved stomach cancer drug Cyramza failed to prolong the lives of patients with advanced liver cancer in a late-stage trial, the drugmaker said on Wednesday.
CHICAGO, June 6- A new way of evaluating tumors may soon help cancer patients identify the underlying genetic link to their disease- and the best possible treatment- all in a single test. "We really are moving away from this one drug, one biomarker, one companion diagnostic," said Dr Richard Pazdur, the U.S. Food and Drug Administration's oncology chief.